BioLineRx and Hemispherian AS Highlight New Data on GLIX1 at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting
BioLineRx and partner Hemispherian AS are presenting two abstracts on GLIX1 at the ASCO 2026 Annual Meeting, highlighting preclinical data and early clinical progress. The first abstract details GLIX1's novel mechanism as a TET2 activator that induces tumor-selective DNA damage, showing strong antitumor activity in glioblastoma models and efficient brain penetration (68-85% of plasma levels). The second abstract demonstrates synergistic antitumor activity when combining GLIX1 with PARP inhibitors across multiple cancer types, providing a rationale for future combination trials.
Key figures
- Drug Name
- GLIX1
- Phase Of Trial
- Phase 1/2a
- Brain exposure pct
- 68-85%
- Trial patients part1
- 30
- Max tolerated dose dogs
- 1000mg/kg
- Max tolerated dose rats
- 2000mg/kg
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.